The MN/CA9 protein Is a tumor-associated antigen that has been shown to have diagnostic utility m identifying cervical dysplasia and carcinoma. MN/CA9 expression is limited to very few normal tissues. We have now extended those observations to further investigate expression of the MN/CA9 protein in histological sections and fine-needle aspiration 
Introduction
RCC3 accounts for approximately2% of all cancers (1) and has traditionally been identified as arising from the proximal tubule of the nephron (2) . Recent studies have further indicated that these carcino mas can also derive from the distal tubules and carry specific cyto genetic alterations (3). However, despite an expanding knowledge of renal cell tumor biology and histogenesis, the incidence of RCC has steadily increased from 1974 through 1990 (1) . It is estimated that there will have been >30,000 new diagnoses of kidney cancer and at least 12,000 deaths from the disease in the United States during 1996 (4). A lack of success in prevention and treatment of RCC is largely due to the inability to detect the early stages of the cancer and the resistance of the cancer cells to conventional modes of treatment, such as radiotherapy and chemotherapy (5). Thus, RCC-specific biomark ers are highly desirable for early diagnosis of the disease and for immunotargeting cancer therapy. In the past decade, several MAbs that react with the proximal tubular epithelium and/or exhibit high specificity for RCC have been described (6, 7) , but their clinical application in diagnosis and treatment of RCC has not been shown.
Here, we describe a new tumor-associated antigen, the MN/CA9
protein, the expression of which correlates with the tumorigenic phenotype of HeLa X fibroblast somatic cell hybrids (8) . The gene encoding the MN/CA9 product is novel: the only identified functional domain to date is a carbonic anhydrase domain. MN/CA9 is now considered to be a new member of the carbonic anhydrase family (9) .
During the examination of normal and neoplastic human tissues, we observed that expression of the MN/CA9 protein is restricted to very few normal tissues but that high levels of MN/CA9 expression are seen in certain malignancies, especially in cervical carcinoma (10, 11 All tissue samplesof benignandmalignantrenalcell lesions were obtained from surgical nephrectomy specimens, with the exception of one adenoma that was taken from autopsy. The tissue samples of normal renal tissues were obtained from surgical specimens, autopsies, and abortions. All of the cyto logicalmaterialswereobtainedfromfine-needleaspirationperformedundera Immunohistochemical Studies. The aspiration cytological smears were decolonzed with 1%acid alcohol and rinsedwith distilled water.Cryostatcut sections (6 ,.@m thick) were fixed in cold acetone for 10 mm, air dried, and washed three times in PBS. Five-Mm sections of paraffin-embedded tissues focal in the cases of papillary RCCs (n = 3) and collecting duct carcinomas (n = 2), (Fig. 1K) . The specimens of chromophobe cell carcinoma were MN/CA9 negative (Fig. 1L) .
MN/CA9 Expression in Metastatic RCCs and NRCCCAs.
MN/CA9 immunoreactivity was observed in all of the metastatic RCCs examined ( Fig. 1M ; Table 2 ). High levels of MN/CA9 expres sion were seen in nine metastatic RCCs; the remaining three cases exhibited focal positivity. In these latter three cases, the MN/CA9-negative cells were morphologically neither granular, clear, nor spin die cell, and had high-grade nuclear atypia.
Immunohistochemical studies were performed on 16 NRCCCAs, which included ovary (n = 8), endometrium (n 3), cervix (n 1), breast (n = 1), prostate (n = 2), and female urethra (n = 1). All of the NRCCCAs studied were MN/CA9 negative ( Fig. iN; MN/CA9 expression was noted in all FNABs ofRCCs (13 of 13). The positivity was both membranous and cytoplasmic and was seen as a diffuse pattern in half of the cases (Fig. 10 ). In two cases, immuno histochemical studies were also performed on duplicate slides, which were air-dried and stained with modified Wright stain (Diff-Quik).
The neoplastic cells in these air-dried smears were MN/CA9 negative, indicating that this processing regimen may result in false negative results. The intensity of the cell staining was significantly improved only in those cases in which relatively weak focal staining was seen in the original procedure (data not shown). There was no effect on MN/ CA9-negative cases.
The Effects of Different Tissue Fixatives on Expression of the
Western Blot Analysis of MNICA9 Expression To determine whether the immunostaining seen with the M75MAb was indeed specific for the MN/CA9 protein, a series of selected frozen speci mens was extracted and subjected to Western blot analysis. The results are depicted in Fig. 2 . The nontumorigenic HeLa X fibroblast hybrid CGL1 and its tumorigenic segregant CGL3 were used as negative and positive controls, respectively. It can be clearly seen that both primary and metastatic RCCs contained the Mr 54,000 and 58,000 bands, indicative of the MN/CA9 protein seen in the CGL3-positive control lane. In contrast, normal kidney and NRCCCA showed complete absence of MN/CA9 protein bands.
Discussion
Solid lesions of the kidney usually are detected radiologically and pose no diagnostic difficulty (14) . However, sometimes the lesions may be small or cystic, and they often exhibit equivocal roentgeno graphic findings. In these instances, the diagnosis may be problematic, especially when the interpretation relies on FNAB materials (15) . It is well known that clear cell adenocarcinoma morphologically identical to RCC can originate from other anatomical sites; therefore, when 2828 were deparaffinized. Immunohistochemical staining, using the anti-MN/CA9 MAb M75 (8) , was done using the avidin-biotin immunoperoxidase technique.
After immunostaining the sections were washed with distilled water, counter stained with hematoxylin, and mounted with permount. Cervical adenocarci noma and normal ectocervix specimens were used as positive and negative controls, respectively, for each run of the immunostain (10). A MAb against j3-actinwas used as a standard control (Sigma Chemical Co., St. Louis, MO) at a dilution of 1:4000.
Results

MN/CA9 Expression in Normal Adult and Fetal Renal Tissues
The normal kidney tissues examined in this study included 14 adult and 6 fetal renal tissues, which were composed of pelvis, medulla, and cortex. The specimens were formalin fixed and paraffin embedded in all cases. In addition, snap-frozen, acetone-fixed sections were also prepared in 10 cases.
All normal adult and fetal kidney sections were MN/CA9 negative (Fig. 1, A and B (Fig. 1, G, H, and 1) . However, the intensity of immunostaining was stronger in the clear cell-containing regions. This was particularly true in cystic clear cell RCC, in which all of the cells lining the cystic wall showed high levels of MN/CA9 expression in the plasma membrane (Fig. 1J) . In contrast, MN/CA9 positivity was 
- â€˜-- Oncocytoma, chromophobe cell carcinoma, and granular cell RCC are three subtypes of RCCs that comprise similar-appearing eosino philic cells. The separation of these tumors sometimes may be diffi cult, and yet it is clinically important because oncocytoma is a benign tumor (19) , and chromophobe cell carcinoma generally has an excel lent prognosis (20) . Most reported cases of malignant oncocytomas have been believed recently to represent RCCs of either the chromo phobic or granular cell type (3) . In this study, oncocytoma and chromophobe cell carcinomas were MN/CA9 negative, but high levels of MN/CA9 protein expression were observed in all cases of granular cell RCC examined. It will be interesting to see, with a larger sample size, whether the differential diagnosis of oncocytoma and granular cell RCC will be enhanced by including MN/CA9 protein expression in the screening process.
On the basis of our findings in this study, we conclude that expression of the MN/CA9 protein appears to be indicative of malig nant transformation of the renal epithelial cell. To test these hypotheses it will be neces sary to undertake a larger clinical trial that is appropriately blinded. These studies are currently under way. 2830 metastatic clear cell RCCs are found in these anatomical sites, prob lems in diagnosis may ensue (16) . In the past decade, MAbs reacting specifically with malignant renal epithelial cells have been identified (6, 7) , but clinically, none of these MAbs have been widely used as diagnostic biomarkers of RCC.
Recently, we described a novel tumor-associated antigen (MN/ CA9), the expression of which is restricted to very few normal tissues but is associated with cervical dysplasia and malignant tumors (10, 11 antigen.
The definition of renal cortical adenoma still remains a controver sial issue. Thus far, it has not been possible to define an unequivocally benign cortical neoplasm using histological, immunohistochemical, and ultrastructural criteria. Although, traditionally, any cortical tu mors less than 3.0 cm in diameter have been regarded as adenomas, it has been reported that such small tumors may give rise to metastases (17) . Indeed, in this study, we observed RCCs that exhibited capsular or vascular invasion and of which the size of tumors was less than 3.0 cm (data not shown). The tumors were of the clear cell type and expressed diffuse MN/CA9 protein immunoreactivity. In contrast, none of the 15 adenomas (sizes ranging from 0.5 to 4.0 cm) tested were MN/CA9 positive. Although further study is needed, the current data strongly indicate that MN/CA9 protein expression may serve as a better biomarker in the separation of renal cortical adenoma from RCC. Radiographically, RCC may present as a cystic lesion, and cystic RCC may be misdiagnosed as a benign unilocular or multilocular cyst (18) . In most cases, extensive sampling of the lesions is required to identify the solid clear cell component along the cystic wall. In the 
